HQP1351
- Generic Name
- HQP1351
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H27F3N6O
- CAS Number
- 1257628-77-5
- Unique Ingredient Identifier
- KV1M7Q3CBP
- Background
HQP1351 is under investigation in clinical trial NCT03883100 (A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation).
- Indication
用于治疗任何酪氨酸激酶抑制剂耐药，并采用经充分验证的检测方法诊断为伴有T315I突变的慢性髓细胞白血病慢性期或加速期的成年患者。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Olverembatinib in SDH-deficient GIST.
- First Posted Date
- 2024-10-14
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06640361
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
- Conditions
- Interventions
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-07-01
- Target Recruit Count
- 82
- Registration Number
- NCT06481228
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Study of Olverembatinib (HQP1351) in Patients With CP-CML
- Conditions
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 285
- Registration Number
- NCT06423911
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06401603
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06390306
- Locations
- 🇨🇳
Peking university people's hospital, Beijing, Beijing, China
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT06051409
- Locations
- 🇦🇺
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Alfred Health, Melbourne, Victoria, Australia
A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-05
- Target Recruit Count
- 22
- Registration Number
- NCT05931757
- Locations
- 🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
- Conditions
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-10-05
- Target Recruit Count
- 60
- Registration Number
- NCT05594784
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Named Patient Program for Olverembatinib (HQP1351)
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Registration Number
- NCT05594758
Olverembatinib for FGFR1-rearranged Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2022-08-30
- Target Recruit Count
- 20
- Registration Number
- NCT05521204
- Locations
- 🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.